A Phase 1, First-in-human, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Food Effect, and Pharmacodynamics Following a Single Oral Dose of IA-14069 in Healthy Male Subjects
Latest Information Update: 05 Jan 2023
At a glance
- Drugs IA-14069 (Primary)
- Indications Inflammation; Rheumatoid arthritis
- Focus Adverse reactions; First in man
- Sponsors iLab
Most Recent Events
- 03 Jan 2023 Status changed from recruiting to completed.
- 06 Sep 2022 The number of treatment arms increased from 4 to 6 accordingly, planned number of patients changed from 32 to 48.
- 06 Sep 2022 Planned End Date changed from 1 Feb 2023 to 1 May 2023.